Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-16T13:23:04.505Z Has data issue: false hasContentIssue false

37 Adherence to treatment in Multiple Sclerosis. The importance of personality, executive functions, and social support

Published online by Cambridge University Press:  21 December 2023

Carlos Alberto Martinez Raudeberg
Affiliation:
Fleni, Capital federal, Buenos aires, Argentina.
Lucia Crivelli*
Affiliation:
Fleni, Capital federal, Buenos Aires, Argentina.
Ismael Calandri
Affiliation:
Fleni, Capital federal, Buenos Aires, Argentina.
Micaela Arruabarrena
Affiliation:
Fleni, Capital federal, Buenos aires, Argentina.
Maria Agustina Piedrabuena
Affiliation:
Fleni, Capital federal, Buenos aires, Argentina.
Maria Agustina Piedrabuena
Affiliation:
Fleni, Capital federal, Buenos aires, Argentina.
Maria Celica Ysrraelit
Affiliation:
Fleni, Capital federal, Buenos aires, Argentina.
Ricardo Allegri
Affiliation:
Fleni, Capital federal, Buenos aires, Argentina.
Jorge Correale
Affiliation:
Fleni, Capital federal, Buenos aires, Argentina.
*
Correspondence: Lucia Crivelli, Fleni ([email protected])
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

To test whether adherence to treatment in patients with MS is influenced by cognitive variables (executive functions), personality, and social support.

Participants and Methods:

This is a pilot observational, descriptive, cross-sectional study. 60 patients with Relapsing remitting MS ( 73.33% female; age: 41.41 ±14.00) undergoing medical treatment ( 28 dymethilfumarate, 7 ocrelizumab/ rituximab, 6 fingolimod, 5 interferon, 5 natalizumab, 4 cladribine, 3 teriflunomide, 1 alemtuzumab, 1 glatiramer acetate) underwent a comprehensive multi-component evaluation including : cognition, social support (using the self-reported record of social support scale), personality (using the NEO-FFI questionnaire) and evaluation of treatment adherence using the Morisky Green Levine Medication Adherence Scale Participants were divided into two groups according to their adherence to medical treatment, low vs. high adherence was defined using a cutoff score of 4. Differences between groups were evaluated using Student's t-test with a significance level of p<0.05, the effect size was calculated with Cohen's d test.

Results:

Groups did not differ significantly in age, sex, type of treatment, Montreal Cognitive Assesments (MoCA) or neuropsychiatric scales of depression and anxiety. Regardless of treatment type, 63.33% of the patients had high treatment adherence. Significant differences between groups were found in the Global Index of Social Support (p=0.016, Cohen's d= 0.73) and the responsibility factor of the NEO-FFI (p=0.048, Cohen's d= 0.20). Conversely, no significant differences were found in executive functions (p=0.8), Openness (p=0.062), Extraversion (p=0.5), Neuroticism (p=0.4) and Agreeableness (p=0.8).

Conclusions:

Social support and the responsibility factor of personality are significantly different between MS patients with high and low adherence to medical treatment. The study of social support and personality may be a key component in improving adherence strategies.

Type
Poster Session 01: Medical | Neurological Disorders | Neuropsychiatry | Psychopharmacology
Copyright
Copyright © INS. Published by Cambridge University Press, 2023